Ticker Details
MacroGenics, Inc. Macrogenics Inc is a clinical-stage biopharmaceutical company. It focusses on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases.
IPO Date:	October 10, 2013
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$107.54M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.48 | 3.08%
Avg Daily Range (30 D):	$0.04 | 2.33%
Avg Daily Range (90 D):	$0.05 | 3.14%

Institutional Daily Volume
Avg Daily Volume:	.58M
Avg Daily Volume (30 D):	.76M
Avg Daily Volume (90 D):	1.12M

Trade Size
Avg Trade Size (Sh.):	113
Avg Trade Size (Sh.) (30 D):	228
Avg Trade Size (Sh.) (90 D):	258

Institutional Trades
Total Institutional Trades:	2,285
Avg Institutional Trade:	$1.67M
Avg Institutional Trade (30 D):	$.66M
Avg Institutional Trade (90 D):	$1.17M
Avg Institutional Trade Volume:	.1M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$1.72M
Avg Closing Trade (30 D):	$.8M
Avg Closing Trade (90 D):	$.8M
Avg Closing Volume:	112.46K

News

Feb 23, 2026 @ 11:14 PM MacroGenics Announces Pausing of Enrollment of New... Source: Macrogenics, Inc.

Jan 14, 2026 @ 8:30 AM [Latest] Global T-Cell Engagers Market Size/Share ... Source: Custom Market Insights

Aug 14, 2025 @ 8:21 PM MacroGenics Revenue Doubles in Q2 Source: Jesterai

Feb 6, 2025 @ 7:40 PM Investigation Alert: MacroGenics, Apellis Pharmace... Source: Johnson Fistel, Llp

Jan 9, 2025 @ 9:52 AM Immunotoxins Market Trends and Regional Business O... Source: Researchandmarkets.Com

Financials
	TTM	Q3 2025	Q2 2025
Basic EPS	$-1.21	$.27	$-.57
Diluted EPS	$-1.21	$.27	$-.57
Revenue	$127.63M	$72.84M	$22.24M
Gross Profit
Net Income / Loss	$-75.89M	$16.82M	$-36.25M
Operating Income / Loss	$-113.58M	$18.64M	$-36.76M
Cost of Revenue	$.23M	$M	$M
Net Cash Flow	$-99.5M	$-50.56M	$-14.88M
PE Ratio